广州泛恩生物科技

FineImmune is a clinical-stage biotechnology company headquartered in Guangzhou, China, specializing in the development of innovative T-cell therapies for solid tumors. The company leverages its proprietary technology platforms, including FineTCR, FineTIL, and FineCAR, to identify and target tumor-specific antigens with high precision. Their lead program, FNC-T703, is a TCR-T therapy targeting GPC3 for the treatment of hepatocellular carcinoma and is currently in clinical trials. Additionally, FineImmune is advancing tumor-infiltrating lymphocyte (TIL) therapies and next-generation CAR-T programs to address various advanced malignancies. By focusing on overcoming the immunosuppressive nature of the tumor microenvironment, the company aims to provide transformative treatments for cancer patients. FineImmune maintains strong collaborations with leading academic institutions like Sun Yat-sen University to accelerate its research and development efforts.